Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-RSV siRNA-MNM
- Development stage
- Preclinical
- Lead developer
- Interna Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intranasal
01
Overview
anti-RSV siRNA-MNM is a preclinical small interfering RNA (siRNA) therapeutic developed by Interna Therapeutics for the treatment of Respiratory Syncytial Virus (RSV) infection. The drug utilizes Interna's proprietary Molecular Nano-Motors (MNM) delivery platform, which is designed to facilitate the intracellular delivery of oligonucleotides without the need for viral vectors or lipid nanoparticles. The siRNA component targets a highly conserved site within the RSV genome, triggering the RNA interference (RNAi) pathway to silence viral gene expression and inhibit replication. It is administered via the intranasal route to directly target the respiratory epithelium, the primary site of RSV infection.
02
Targets
Respiratory syncytial virus nucleoprotein mRNA
Beyond the preview
Go deeper on anti-RSV siRNA-MNM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-RSV siRNA-MNM.